Literature DB >> 21534959

Dopamine-dependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2).

Yuriko Iwakura1, Ran Wang, Yuichi Abe, Ying-Shan Piao, Yuji Shishido, Shigeki Higashiyama, Nobuyuki Takei, Hiroyuki Nawa.   

Abstract

Epidermal growth factor (EGF) and structurally related peptides promote neuronal survival and the development of midbrain dopaminergic neurons; however, the regulation of their production has not been fully elucidated. In this study, we found that the treatment of striatal cells with dopamine agonists enhances EGF release both in vivo and in vitro. We prepared neuron-enriched and non-neuronal cell-enriched cultures from the striatum of rat embryos and challenged those with various neurotransmitters or dopamine receptor agonists. Dopamine and a dopamine D(1) -like receptor agonist (SKF38393) triggered EGF release from neuron-enriched cultures in a dose-dependent manner. A D(2) -like agonist (quinpirole) increased EGF release only from non-neuronal cell-enriched cultures. The EGF release from striatal neurons and non-neuronal cells was concomitant with ErbB1 phosphorylation and/or with the activation of a disintegrin and metalloproteinase and matrix metalloproteinase. The EGF release from neurons was attenuated by an a disintegrin and metalloproteinase/matrix metalloproteinase inhibitor, GM6001, and a calcium ion chelator, BAPTA/AM. Transfection of cultured striatal neurons with alkaline phosphatase-tagged EGF precursor cDNA confirmed that dopamine D(1) -like receptor stimulation promoted both ectodomain shedding of the precursor and EGF release. Therefore, the activation of striatal dopamine receptors induces shedding and release of EGF to provide a retrograde neurotrophic signal to midbrain dopaminergic neurons.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21534959     DOI: 10.1111/j.1471-4159.2011.07295.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Dopamine Increases CD14+CD16+ Monocyte Transmigration across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis.

Authors:  Tina M Calderon; Dionna W Williams; Lillie Lopez; Eliseo A Eugenin; Laura Cheney; Peter J Gaskill; Mike Veenstra; Kathryn Anastos; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2017-01-29       Impact factor: 4.147

2.  Dopamine D2 receptor-mediated epidermal growth factor receptor transactivation through a disintegrin and metalloprotease regulates dopaminergic neuron development via extracellular signal-related kinase activation.

Authors:  Sehyoun Yoon; Ja-Hyun Baik
Journal:  J Biol Chem       Date:  2013-08-16       Impact factor: 5.157

3.  Elevation of EGR1/zif268, a Neural Activity Marker, in the Auditory Cortex of Patients with Schizophrenia and its Animal Model.

Authors:  Yuriko Iwakura; Ryoka Kawahara-Miki; Satoshi Kida; Hidekazu Sotoyama; Ramil Gabdulkhaev; Hitoshi Takahashi; Yasuto Kunii; Mizuki Hino; Atsuko Nagaoka; Ryuta Izumi; Risa Shishido; Toshiyuki Someya; Hirooki Yabe; Akiyoshi Kakita; Hiroyuki Nawa
Journal:  Neurochem Res       Date:  2022-04-25       Impact factor: 4.414

4.  Dopamine increases NMDA-stimulated calcium flux in striatopallidal neurons through a matrix metalloproteinase-dependent mechanism.

Authors:  Yan Li; John Partridge; Carissa Berger; Alberto Sepulveda-Rodriguez; Stefano Vicini; Katherine Conant
Journal:  Eur J Neurosci       Date:  2016-01       Impact factor: 3.386

5.  Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.

Authors:  Hidekazu Sotoyama; Yingjun Zheng; Yuriko Iwakura; Makoto Mizuno; Miho Aizawa; Ksenia Shcherbakova; Ran Wang; Hisaaki Namba; Hiroyuki Nawa
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

6.  Glutamate-dependent ectodomain shedding of neuregulin-1 type II precursors in rat forebrain neurons.

Authors:  Yuriko Iwakura; Ran Wang; Naoko Inamura; Kazuaki Araki; Shigeki Higashiyama; Nobuyuki Takei; Hiroyuki Nawa
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

7.  ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.

Authors:  M Mizuno; H Sotoyama; H Namba; M Shibuya; T Eda; R Wang; T Okubo; K Nagata; Y Iwakura; H Nawa
Journal:  Transl Psychiatry       Date:  2013-04-30       Impact factor: 6.222

Review 8.  Activity dependent CAM cleavage and neurotransmission.

Authors:  Katherine Conant; Megan Allen; Seung T Lim
Journal:  Front Cell Neurosci       Date:  2015-08-11       Impact factor: 5.505

Review 9.  Neuropathologic implication of peripheral neuregulin-1 and EGF signals in dopaminergic dysfunction and behavioral deficits relevant to schizophrenia: their target cells and time window.

Authors:  Hiroyuki Nawa; Hidekazu Sotoyama; Yuriko Iwakura; Nobuyuki Takei; Hisaaki Namba
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

10.  Dopamine Receptor Activation Modulates the Integrity of the Perisynaptic Extracellular Matrix at Excitatory Synapses.

Authors:  Jessica Mitlöhner; Rahul Kaushik; Hartmut Niekisch; Armand Blondiaux; Christine E Gee; Max F K Happel; Eckart Gundelfinger; Alexander Dityatev; Renato Frischknecht; Constanze Seidenbecher
Journal:  Cells       Date:  2020-01-21       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.